This content is in French.
mHSPC: the winning trio?
27 novembre 2025
By Ana Espino | Published on November 27, 2025 | 3 min readMetastatic hormone-sensitive prostate cancer (mHSPC) is an advanced stage of the disease, with a prognosis that remains concerning despite recent therapeutic advances. Standard treatment is based on androgen deprivation therapy (ADT), to which agents such as docetaxel or androgen receptor–targeted therapies (ARATs)—including enzalutamide,
Metastatic hormone-sensitive prostate cancer (mHSPC) is an advanced stage of the disease, with a prognosis that remains concerning despite recent therapeutic advances. Standard treatment is based on androgen deprivation therapy (ADT), to which agents such as docetaxel or androgen receptor–targeted therapies (ARATs)—including enzalutamide, apalutamide, abiraterone, and more recently darolutamide—may be added.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Wang, H., et al. (2025). Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. Scientific reports, 15(1), 39857
View the source
